Skip to main content
RPbio Inc. logo

RPbio Inc. — Investor Relations & Filings

Ticker · 314140 ISIN · KR7314140005 KO Manufacturing
Open in API
Filings indexed 93 across all filing types
Latest filing 2022-10-07 Director's Dealing
Country KR South Korea
Listing KO 314140

About RPbio Inc.

https://rpbio.co.kr/html/en/main.php

RPbio Inc. is a bio-health company specializing in the development and production of pharmaceuticals and health functional foods. Established in 1983 as a joint venture with RP Scherer, the company is a leading producer of soft capsules, leveraging extensive technological expertise. RPbio operates as a Contract Development and Manufacturing Organization (CDMO), providing comprehensive services that include research and development, raw material sourcing, manufacturing of finished drugs, and OEM/ODM for health supplements. The company focuses on advancing softgel technologies and offers integrated solutions, including regulatory support, to its global partners in the pharmaceutical and health sectors.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details the share ownership and changes in holdings for a specific executive (Lee Myung Hee) of RP Bio. This type of filing is a standard disclosure for insider share transactions and holdings, which corresponds to the 'Director's Dealing' category.
2022-10-07 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Financial Supervisory Service (증권선물위원회) and the Korea Exchange. This is a standard regulatory filing in South Korea used to disclose insider shareholdings and transactions by directors or major shareholders. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives.
2022-10-07 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. This document specifically details the acquisition and change in shareholding percentage by '마이다스제1호사모투자 합자회사' in '주식회사 알피바이오'. Since this is a formal notification of a major shareholding threshold change (crossing 5% or significant ownership), it falls under the 'Major Shareholding Notification' category.
2022-10-06 Korean
기타경영사항(자율공시)(전환우선주의 보통주 전환청구)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from RP Bio regarding the conversion of convertible preferred shares into common shares. This involves a change in the company's capital structure and share count. According to the provided definitions, announcements regarding new share issues or capital changes fall under the 'SHA' category.
2022-09-30 Korean
증권발행실적보고서
Share Issue/Capital Change Classification · 100% confidence The document is a '증권발행실적보고서' (Report on the Results of Securities Issuance) filed with the Financial Supervisory Service (FSS) in South Korea. This document provides detailed information regarding the final results of a public offering, including subscription and allocation data, shareholding changes, and the use of proceeds. This type of filing is a standard regulatory requirement following an IPO or capital raise, which falls under the category of 'Share Issue/Capital Change' (SHA) as it details the issuance of new shares and the resulting capital structure changes.
2022-09-23 Korean
[발행조건확정]증권신고서(지분증권)
Capital/Financing Update Classification · 98% confidence The document is a '증권신고서(지분증권) 정정신고서' (Securities Registration Statement - Amendment) filed with the Financial Services Commission (금융위원회) in South Korea. It details the finalization of the offering price (공모가액 확정) for RP Bio (알피바이오) and includes updated terms for the public offering, such as the final price, total offering amount, and allocation ratios. This document is a formal regulatory filing related to a capital raise and share issuance process. Given the specific nature of the document as a formal registration statement amendment for a public offering, it falls under the 'Regulatory Filings' category as the most appropriate fallback for this type of financial disclosure.
2022-09-19 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.